Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dopamine | 34 | 2022 | 232 | 6.970 |
Why?
|
| Cocaine | 22 | 2020 | 256 | 3.980 |
Why?
|
| Dopamine Uptake Inhibitors | 16 | 2018 | 117 | 3.070 |
Why?
|
| Nucleus Accumbens | 15 | 2022 | 94 | 2.750 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 18 | 2022 | 97 | 2.470 |
Why?
|
| Receptors, Nicotinic | 4 | 2022 | 59 | 2.080 |
Why?
|
| Rats | 23 | 2022 | 1596 | 1.520 |
Why?
|
| Rats, Sprague-Dawley | 19 | 2020 | 743 | 1.300 |
Why?
|
| Animals | 39 | 2022 | 7542 | 1.280 |
Why?
|
| Circadian Rhythm | 2 | 2022 | 43 | 1.270 |
Why?
|
| Self Administration | 14 | 2016 | 297 | 1.160 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 4 | 2022 | 7 | 1.080 |
Why?
|
| Motor Activity | 7 | 2020 | 325 | 1.000 |
Why?
|
| Presynaptic Terminals | 5 | 2018 | 37 | 1.000 |
Why?
|
| Corpus Striatum | 3 | 2015 | 60 | 0.930 |
Why?
|
| Exploratory Behavior | 4 | 2022 | 30 | 0.920 |
Why?
|
| Synaptic Transmission | 3 | 2014 | 117 | 0.850 |
Why?
|
| Nicotinic Agonists | 2 | 2020 | 39 | 0.830 |
Why?
|
| Amphetamine | 6 | 2015 | 37 | 0.780 |
Why?
|
| Brain | 7 | 2015 | 951 | 0.770 |
Why?
|
| Receptor, Muscarinic M1 | 1 | 2020 | 1 | 0.730 |
Why?
|
| Locomotion | 2 | 2020 | 31 | 0.720 |
Why?
|
| Nicotine | 2 | 2020 | 174 | 0.710 |
Why?
|
| Electrochemical Techniques | 5 | 2014 | 23 | 0.700 |
Why?
|
| Methylphenidate | 6 | 2015 | 36 | 0.690 |
Why?
|
| Central Nervous System Stimulants | 7 | 2015 | 76 | 0.670 |
Why?
|
| HIV-1 | 2 | 2022 | 45 | 0.570 |
Why?
|
| Amphetamines | 2 | 2013 | 6 | 0.550 |
Why?
|
| Phenmetrazine | 1 | 2016 | 4 | 0.550 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2016 | 24 | 0.540 |
Why?
|
| Amino Acids | 1 | 2016 | 46 | 0.540 |
Why?
|
| Male | 27 | 2020 | 19218 | 0.520 |
Why?
|
| Motivation | 1 | 2016 | 113 | 0.510 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2016 | 633 | 0.510 |
Why?
|
| Extracellular Space | 1 | 2014 | 25 | 0.480 |
Why?
|
| Nerve Tissue Proteins | 2 | 2015 | 120 | 0.470 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2014 | 36 | 0.460 |
Why?
|
| Exocytosis | 1 | 2013 | 10 | 0.440 |
Why?
|
| Synapses | 3 | 2015 | 83 | 0.440 |
Why?
|
| Neostriatum | 1 | 2013 | 22 | 0.440 |
Why?
|
| Electric Stimulation | 5 | 2016 | 104 | 0.420 |
Why?
|
| Cholinergic Agents | 2 | 2022 | 8 | 0.390 |
Why?
|
| Microdialysis | 4 | 2014 | 34 | 0.380 |
Why?
|
| HIV Infections | 2 | 2022 | 395 | 0.360 |
Why?
|
| Drug Tolerance | 5 | 2013 | 32 | 0.360 |
Why?
|
| Cocaine-Related Disorders | 5 | 2016 | 99 | 0.330 |
Why?
|
| Receptors, Dopamine D2 | 4 | 2015 | 79 | 0.330 |
Why?
|
| Wakefulness | 1 | 2009 | 25 | 0.330 |
Why?
|
| Receptors, Dopamine | 2 | 2013 | 20 | 0.320 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 2016 | 94 | 0.310 |
Why?
|
| Neurotoxins | 1 | 2008 | 16 | 0.310 |
Why?
|
| Nervous System Diseases | 1 | 2008 | 39 | 0.300 |
Why?
|
| Receptors, Adrenergic | 1 | 2007 | 7 | 0.300 |
Why?
|
| Time Factors | 6 | 2015 | 2151 | 0.300 |
Why?
|
| Tyrosine 3-Monooxygenase | 4 | 2015 | 23 | 0.290 |
Why?
|
| Ventral Tegmental Area | 3 | 2016 | 31 | 0.290 |
Why?
|
| Mice | 11 | 2022 | 2484 | 0.290 |
Why?
|
| Social Isolation | 2 | 2018 | 45 | 0.280 |
Why?
|
| Substance-Related Disorders | 1 | 2008 | 128 | 0.280 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2007 | 92 | 0.280 |
Why?
|
| Mice, Knockout | 6 | 2016 | 443 | 0.250 |
Why?
|
| Behavior, Animal | 4 | 2016 | 250 | 0.230 |
Why?
|
| Central Nervous System Depressants | 2 | 2014 | 63 | 0.220 |
Why?
|
| Reward | 2 | 2022 | 64 | 0.220 |
Why?
|
| Mice, Transgenic | 4 | 2022 | 264 | 0.220 |
Why?
|
| Acetylcholine | 2 | 2020 | 48 | 0.210 |
Why?
|
| Conditioning, Classical | 1 | 2022 | 26 | 0.200 |
Why?
|
| Ethanol | 2 | 2014 | 189 | 0.200 |
Why?
|
| Neurons | 3 | 2015 | 410 | 0.180 |
Why?
|
| Receptor, Muscarinic M4 | 1 | 2020 | 6 | 0.180 |
Why?
|
| Mice, Inbred C57BL | 7 | 2016 | 767 | 0.170 |
Why?
|
| Random Allocation | 2 | 2010 | 228 | 0.170 |
Why?
|
| Vesicular Monoamine Transport Proteins | 1 | 2018 | 5 | 0.160 |
Why?
|
| Analysis of Variance | 4 | 2015 | 464 | 0.160 |
Why?
|
| Nomifensine | 2 | 2022 | 3 | 0.160 |
Why?
|
| Conditioning, Operant | 2 | 2015 | 88 | 0.150 |
Why?
|
| Tissue Culture Techniques | 2 | 2014 | 40 | 0.150 |
Why?
|
| Stress, Psychological | 1 | 2018 | 222 | 0.140 |
Why?
|
| Blotting, Western | 2 | 2014 | 289 | 0.140 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 288 | 0.130 |
Why?
|
| Adaptation, Biological | 1 | 2014 | 8 | 0.120 |
Why?
|
| Infusions, Intravenous | 1 | 2015 | 100 | 0.120 |
Why?
|
| Humans | 6 | 2022 | 32115 | 0.120 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2014 | 4 | 0.120 |
Why?
|
| Models, Neurological | 1 | 2015 | 117 | 0.120 |
Why?
|
| Biophysical Phenomena | 1 | 2014 | 6 | 0.120 |
Why?
|
| Patch-Clamp Techniques | 1 | 2014 | 75 | 0.120 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 77 | 0.120 |
Why?
|
| Membrane Potentials | 1 | 2014 | 81 | 0.120 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 495 | 0.110 |
Why?
|
| Action Potentials | 1 | 2014 | 178 | 0.110 |
Why?
|
| Regression Analysis | 2 | 2014 | 293 | 0.110 |
Why?
|
| Neuronal Plasticity | 1 | 2013 | 80 | 0.100 |
Why?
|
| Benztropine | 1 | 2012 | 2 | 0.100 |
Why?
|
| Bupropion | 1 | 2012 | 5 | 0.100 |
Why?
|
| Histamine H1 Antagonists | 1 | 2012 | 9 | 0.100 |
Why?
|
| Mutation | 1 | 2014 | 489 | 0.100 |
Why?
|
| Piperidines | 1 | 2012 | 118 | 0.090 |
Why?
|
| HIV | 1 | 2008 | 24 | 0.080 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2008 | 19 | 0.080 |
Why?
|
| Methamphetamine | 1 | 2008 | 17 | 0.080 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2007 | 6 | 0.070 |
Why?
|
| Fluoxetine | 1 | 2007 | 16 | 0.070 |
Why?
|
| Autoradiography | 1 | 2007 | 45 | 0.070 |
Why?
|
| Neural Pathways | 1 | 2008 | 94 | 0.070 |
Why?
|
| Dopamine Antagonists | 1 | 2007 | 22 | 0.070 |
Why?
|
| Brain Chemistry | 1 | 2007 | 29 | 0.070 |
Why?
|
| Benzazepines | 1 | 2007 | 21 | 0.070 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2007 | 42 | 0.070 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2007 | 33 | 0.070 |
Why?
|
| Receptors, Dopamine D3 | 1 | 2007 | 33 | 0.070 |
Why?
|
| Rats, Long-Evans | 2 | 2018 | 72 | 0.070 |
Why?
|
| Clonidine | 1 | 2007 | 62 | 0.070 |
Why?
|
| Sex Characteristics | 1 | 2007 | 173 | 0.070 |
Why?
|
| Microelectrodes | 2 | 2016 | 16 | 0.070 |
Why?
|
| Dopamine Agents | 2 | 2015 | 19 | 0.060 |
Why?
|
| Pregnancy | 1 | 2007 | 997 | 0.060 |
Why?
|
| Age Factors | 2 | 2018 | 1189 | 0.060 |
Why?
|
| Putamen | 1 | 2022 | 25 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2022 | 46 | 0.050 |
Why?
|
| Tropanes | 1 | 2016 | 9 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2018 | 406 | 0.040 |
Why?
|
| Models, Animal | 1 | 2016 | 169 | 0.030 |
Why?
|
| Phosphinic Acids | 1 | 2015 | 2 | 0.030 |
Why?
|
| Gene Knock-In Techniques | 1 | 2015 | 9 | 0.030 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2015 | 6 | 0.030 |
Why?
|
| Extracellular Fluid | 1 | 2015 | 11 | 0.030 |
Why?
|
| Propanolamines | 1 | 2015 | 11 | 0.030 |
Why?
|
| Interneurons | 1 | 2015 | 22 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2015 | 114 | 0.030 |
Why?
|
| Artifacts | 1 | 2015 | 39 | 0.030 |
Why?
|
| Tritium | 1 | 2015 | 14 | 0.030 |
Why?
|
| 4-Aminopyridine | 1 | 2015 | 6 | 0.030 |
Why?
|
| Potassium Channel Blockers | 1 | 2015 | 9 | 0.030 |
Why?
|
| Synaptosomes | 1 | 2015 | 17 | 0.030 |
Why?
|
| Mecamylamine | 1 | 2014 | 11 | 0.030 |
Why?
|
| Nicotinic Antagonists | 1 | 2014 | 17 | 0.030 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2015 | 75 | 0.030 |
Why?
|
| Biological Transport | 1 | 2014 | 69 | 0.030 |
Why?
|
| Mice, Inbred DBA | 1 | 2014 | 40 | 0.030 |
Why?
|
| Species Specificity | 1 | 2014 | 90 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2015 | 96 | 0.030 |
Why?
|
| Protein Binding | 1 | 2015 | 201 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 208 | 0.030 |
Why?
|
| Fenfluramine | 1 | 2014 | 4 | 0.030 |
Why?
|
| Serotonin Agents | 1 | 2014 | 5 | 0.030 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2014 | 5 | 0.030 |
Why?
|
| Space Perception | 1 | 2014 | 27 | 0.030 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2014 | 19 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2015 | 166 | 0.030 |
Why?
|
| Stereotyped Behavior | 1 | 2013 | 13 | 0.030 |
Why?
|
| Stimulation, Chemical | 1 | 2013 | 13 | 0.030 |
Why?
|
| Electrochemistry | 1 | 2013 | 14 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2016 | 682 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2013 | 187 | 0.030 |
Why?
|
| Spatial Behavior | 1 | 2012 | 11 | 0.030 |
Why?
|
| Psychomotor Agitation | 1 | 2012 | 10 | 0.030 |
Why?
|
| Kinetics | 1 | 2012 | 209 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 198 | 0.020 |
Why?
|
| Calcium | 1 | 2013 | 307 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 229 | 0.020 |
Why?
|
| Female | 1 | 2007 | 20016 | 0.020 |
Why?
|